Larry L. Wood, the President and CEO of Procept BioRobotics Corporation (PRCT +1.09%), reported an indirect purchase of 23,900 shares of common stock on August 7, 2026. SEC Form 4 filing.
Today’s Change
(1.09%) $0.23
Current Price
$21.32
Key Data Points
Market Cap
Day’s Range
$21.10 – $21.88
52wk Range
$16.66 – $42.43
Volume
819.4K
Avg Vol
1.6M
Gross Margin
63.74%
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$498,000 |
| Post-transaction value | $6.9 million |
| Post-transaction shares (directly held) | ~314,000 |
| Post-transaction shares (indirectly held) | 23,900 |
Transaction value based on SEC Form 4 weighted average purchase price ($20.85); post-transaction value based on August 7, 2026 market close ($20.41).
Key questions
- What is the significance of the acquisition structure?
The 23,900 shares were purchased by The Larry Wood Trust, establishing a new indirect ownership base alongside the CEO’s existing direct holdings of ~314,000 shares. - How does this move align with the company’s current valuation?
Wood executed this purchase at $20.85 per share, which is slightly above the $20.41 market close on the transaction date, while the stock is down 48% on a one-year basis as of August 7, 2026. - What is the broader insider ownership context?
Following this transaction, Wood holds a total beneficial interest of 338,103 shares, contributing to an aggregate insider ownership level of 0.59% in the $1.2 billion (market cap) medical technology firm. - What are the fundamental considerations for the company?
The purchase comes as the San Jose-based firm reports trailing twelve months revenue of $337.3 million, though it continues to operate with a net loss of $109.8 million over the same period.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-07) | $20.41 |
| Market Capitalization | $1.2 billion |
| Revenue (TTM) | $337.3 million |
| Net Income (TTM) | -$109.8 million |
Company Snapshot
- Procept BioRobotics develops and commercializes the AquaBeam Robotic System, a minimally invasive surgical robot that performs Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH) in male patients, representing the company’s primary revenue source.
- The company generates revenue through the sale of robotic surgical systems, consumable supplies, and service agreements to healthcare providers and hospitals seeking advanced urological treatment solutions.
- Procept BioRobotics primarily targets urology departments and surgical centers within hospitals and ambulatory surgical centers that treat patients with lower urinary tract symptoms related to BPH.
Procept BioRobotics is a San Jose-based medical device manufacturer with 888 employees operating in the surgical robotics sector. The company generated $337.3 million in trailing twelve month (TTM) revenue while operating at a net loss of $109.8 million, reflecting the capital-intensive nature of robotic surgical technology development and market expansion. Procept’s competitive differentiation centers on its proprietary Aquablation technology platform and image-guided robotic system, which addresses a significant clinical need in minimally invasive urological procedures.
What this transaction means for investors
There are multiple reasons a company insider may sell shares in the business. One reason could be the need to raise cash to meet a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company’s future.
However, there is only one reason an insider buys stock: they believe the share price is going up.
By that investor’s rule of thumb, Wood’s purchase of half-a-million dollars worth of Procept shares is bullish. Adding to the bullishness is the fact that studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.
Wood has been CEO of the business since September of 2025 and a director off the company since spring 2024, so he knows the operation inside and out.
Procept had been in a slump that Procept appears to be coming out of, thanks to a reorganization led by Wood to better focus the company’s resources. In its second quarter, reported at the start of the month, Procept reported a sales rise of 19%. Because its systems are a significant investment for hospitals at about $495,000 per Hydros system, every sale means predictable revenue for the future. Wood told investors he believes the reorganization and the increasing appeal of the Hydros system have laid the ground for long term profitability and margin expansion. His purchase puts his money where his mouth is.
An insider purchase does not guarantee shares will rally over the long-term but it’s a crucial signal for investors to examine the fundamentals of the business to see if they can catch a rising tide before much of the market sees the same opportunity.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
